Company:
AstraZeneca Pharmaceuticals (Ireland) DACStatus:
UpdatedLegal Category:
Product subject to medical prescription which may not be renewed (A)Active Ingredient(s):
This medicinal product is subject to additional monitoring.
*Additional information is available within the SPC or upon request to the company
Product Notice
Discontinued Strength Notice
Ondexxya 200 mg powder for solution for infusion, 5-vial pack size - EU/1/18/1345/002 will be discontinued as of 04 December 2026. Please note that Ondexxya 200 mg powder for solution for infusion, 4-vial pack size (EU/1/18/1345/001) will remain available on the market.
AstraZeneca Pharmaceuticals (Ireland) DAC
 DAC.webp)
Address:
College Business and Technology Park, Blanchardstown Road North, Dublin 15, D15 R925Medical Information E-mail:
mipqc.ireland@astrazeneca.comTelephone:
+353 1 609 7100Fax:
+353 1 686 5038Website:
https://contactazmedical.astrazeneca.comMedical Information Direct Line:
1800 800 899